Novus to distribute AmideBio’s peptides

BOULDER – Novus Biologicals LLC in Littleton has agreed to distribute Boulder-based AmideBio’s line of peptides to bioscience researchers worldwide. 

AmideBio develops and manufactures peptides based on intellectual property licensed from the University of Colorado that was developed by CU professor Michael Stowell, who also is AmideBio’s chief technology officer.

Stowell’s manufacturing technique has the potential to reduce costs and to make it feasible to manufacture drugs that were previously difficult to produce with conventional methods. 

SPONSORED CONTENT

How dispatchable resources enable the clean energy transition

Platte River must prepare for the retirement of 431 megawatts (MW) of dispatchable, coal-fired generation by the end of the decade and address more frequent extreme weather events that can bring dark calms (periods when there is no sun or wind).

Initial commercial efforts will focus on Novus’ distribution of the Amyloid family of peptides for the study of Alzheimer’s disease. The peptides will be available from Novus’s worldwide headquarters in Littleton and from Novus Europe based in Cambridge, United Kingdom.

Novus and AmideBio are both members of the Colorado BioScience Association, an organization that facilitates the growth of the industry in Colorado through advocacy, representation and service.